Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pee Cee Cosma Sope Limited (PCCOSMA.BO)
Agra, IN
Pee Cee Cosma Sope Ltd. specializes in the production of a diverse range of personal care and household cleaning items. Their extensive product line features soaps, detergents, cleaning and polishing products, perfumes, and other toiletries. Specific offerings include laundry soap, powdered detergent, and solid detergent cakes, all marketed under their "Doctor Soap" brand. This company was established in 1947 by P. C. Jain and has its headquarters situated in Agra, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.45% | -2.76% | -8.19% | -10.40% | -19.60% | -17.86% | -34.12% | +80.12% | +127.43% | +327.60% | +1,187.22% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Household & Personal Products: +3.3%+9.4% ★ Q1'26: +19.8% (vs Q1'25)
-
EPS growth Household & Personal Products: +8.8%-13.5% Q1'26: +50.0% (vs Q1'25)
-
FCF margin FCF growth · Household & Personal Products: +44.8%+9.2% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Household & Personal Products: +9.9%+7.0% Q1'26: +6.4% (vs Q1'25)
-
ROIC Household & Personal Products: +8.2%+23.6% ★ Q1'26: +23.7% (vs Q1'25)
-
Share dilution Household & Personal Products: +0.2%-0.2% Q1'26: -0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Household & Personal Products: -0.51×0.03× ★ Q1'26: 0.03× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-25 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mayank Mahendra Jain | Executive Chairman | 4M | male |
| Ankit Ashok Kumar Jain | MD & Director | 4M | male |
| Brij Mohan Verma | Chief Financial Officer | — | male |
| Mayank Sharma | General Manager of Operations | — | — |
| Nidhi Agarwal | Compliance Officer & Company Secretary | — | female |
| Pavnesh Sharma | Vice President of Sales | — | — |
| Sanjay Nagar | Sales Manager | — | — |
| Ved Prakash Duvey | PA & IR Manager | — | — |
| Avinash Chand Garg | Accounts Executive | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PCCOSMA.BO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
